Literature DB >> 24881766

Boolean immunotherapy: reversal of fortune.

Richard A Morgan1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24881766      PMCID： PMC4048909          DOI： 10.1038/mt.2014.75

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

1.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

Authors:  James N Kochenderfer; Mark E Dudley; Steven A Feldman; Wyndham H Wilson; David E Spaner; Irina Maric; Maryalice Stetler-Stevenson; Giao Q Phan; Marybeth S Hughes; Richard M Sherry; James C Yang; Udai S Kammula; Laura Devillier; Robert Carpenter; Debbie-Ann N Nathan; Richard A Morgan; Carolyn Laurencot; Steven A Rosenberg
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.

Authors:  Chen Ankri; Katerina Shamalov; Miryam Horovitz-Fried; Shmuel Mauer; Cyrille J Cohen
Journal:  J Immunol       Date:  2013-09-11       Impact factor: 5.422

3.  Quantitative control of intracellular signaling activity through chimeric receptors incorporating multiple identical tyrosine motifs.

Authors:  Koichiro Saka; Masahiro Kawahara; Teruyuki Nagamune
Journal:  Biotechnol Bioeng       Date:  2013-11-27       Impact factor: 4.530

Review 4.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

Review 6.  Deciphering and reversing tumor immune suppression.

Authors:  Greg T Motz; George Coukos
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

7.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

8.  Reversal of tumor immune inhibition using a chimeric cytokine receptor.

Authors:  Ann M Leen; Sujita Sukumaran; Norihiro Watanabe; Somala Mohammed; Jacqueline Keirnan; Ryu Yanagisawa; Usanarat Anurathapan; David Rendon; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Juan F Vera
Journal:  Mol Ther       Date:  2014-03-20       Impact factor: 11.454

9.  Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.

Authors:  Scott Wilkie; May C I van Schalkwyk; Steve Hobbs; David M Davies; Sjoukje J C van der Stegen; Ana C Parente Pereira; Sophie E Burbridge; Carol Box; Suzanne A Eccles; John Maher
Journal:  J Clin Immunol       Date:  2012-04-17       Impact factor: 8.317

Review 10.  Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.

Authors:  Christel Devaud; Liza B John; Jennifer A Westwood; Phillip K Darcy; Michael H Kershaw
Journal:  Oncoimmunology       Date:  2013-08-22       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.